WELCOME TO Nectin Therapeutics FIND OUT MORE Nectin Therapeutics is a Biotechnology Company Pioneering the Development of Next Generation Immune Oncology Therapies
The problem we are trying to address

Despite the unprecedented efficacy of existing immunotherapy agents...

…many patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered novel resistance mechanisms and developed novel agents targeting these mechanisms for improved therapy. Our antibodies target the unique tumor biology of the nectin pathways and demonstrate stand-alone efficacy and unprecedented synergy when combined with each other or with PD(L)-1 inhibitors.

Nectin’s pipeline includes innovative first-in-class and best-in-class programs, utilizing internal expertise as well as collaborative efforts.

Diverse pipeline of targeted immunotherapies including: Novel immuno-oncology (IO) antibodies, ADCs, CAR-T and CAR-NK cell technology.

Lead asset, an anti-PVR antibody is 12 months from IND. PVR is emerging as rate limiting factor for approved immune checkpoint inhibitors.

Our Mission

  • Unlocking the power of the immune system by developing a constellation of next-generation immunotherapy agents
  • Our antibodies target the unique tumor biology of the nectin pathways
  • This demonstrates the stand-alone efficacy and unprecedented synergy when combined with each other or with PD(L)-1 inhibitors